Global Liver Cancer Drugs Market

Liver Cancer Drugs Market Insights

Liver cancer is a persistent, life-threatening, and progressing disease that progresses in liver cells. The liver is one of the main functional organs in the body found on the upper right side of the abdomen under the right lung. The liver mainly generates enzymes and bile to aid in the digestion of food. It also creates blood clotting enzymes that purify the blood by eliminating infectious substances. The liver performs numerous other significant functions, for example, eliminating toxic substances and other hazardous things from the blood and preparing them for discharge. Primary hepatic cancer, which starts in hepatocyte cells, and secondary hepatic cancer, which extends to the liver from various areas of the body, are two categories of liver cancer. The latter form of cancer, known as metastatic cancer, is more prevalent.

As per a study conducted in Liver Cancer Journal 2020 by Chan S.L. et al., COVID-19 aggravates the underlying chronic liver disease and oversimplifies cancer treatment in patients with hepatocellular carcinoma (HCC). Cancer patients, specifically those who have subsequently completed cancer therapy, are at a greater likelihood of disease and devastating consequences.

The increasing prevalence of liver cancer, expanding R&D expenditures for the advancement of new drugs, and government measures to raise cancer consciousness are the primary drivers influencing the market growth. The modern way of living has exposed a significant portion of the population to some trigger variables that lead to liver cancer. Diabetes, hepatitis, cardiovascular conditions, high body weight, alcohol intake, and smoking are among the potential variables.

As per GLOBOCAN reports, there were approximately 905,677 (4.7 percent) new liver cancer patients and 830,180 (8.3 percent) deaths related to liver cancer in 2020. Furthermore, the increasing potential for therapeutic drugs for liver cancer will provide many prospects for industry participants to manufacture additional drugs, and the market is presumed to expand significantly throughout the forecast period. Nevertheless, considerations such as adverse effects correlated with some drugs, as well as the high price of cancer treatments and a strict regulatory environment, are likely to stymie demand growth over the projected period.

Through the forecast period, the liver cancer therapeutics market is likely to be driven by the rising incidence of metastatic cancer that progresses from other areas of the body, such as pancreatic cancer, colorectal cancer, or breast cancer. The discovery of new advanced therapeutic drugs, a robust clinical portfolio of therapeutic drugs, increased global recognition, and favorable government funding are all expected to lead to the development of the liver cancer therapeutics market.

Globally, the rise in the prevalence of liver cancer has elevated it to the second leading reason of mortality behind only cardiovascular disease. Its prominence is mostly due to environmental conditions, alcohol intake, smoking, and rising urbanization. As a result, predominance and demand for successful medicines are expected to fuel market growth throughout the forecast period. Cancer research and advancement to deliver innovative health treatment are advancing at a rapid pace. Revolutionary trials contributing to combined therapy with novel or established drug compounds have increased the number of applicants in the pipeline for liver cancer treatment. Furthermore, robust support for research & development grants from government & international healthcare organizations is critical to expanding the liver cancer business prospects. This, along with an increasing demand for biosimilars entering the market, is expected to boost the global market growth.

Liver Cancer Drugs: By Therapeutic Class

Based on therapeutic class, liver cancer drugs can be segregated into targeted therapy and immunotherapy.  Targeted therapy is the leading segment as per therapeutics class, the reason being is that patients being treated with medicines have been showing more improvement than the ones with immunotherapy. The success rate of reduction of symptoms through targeted therapy has been almost equal to 75%. Targeted therapy focuses on systematically destroying tumor cells while alleviating adverse effects on symptomatic cells. This consideration contributes to more excellent drug recommendations by hospitals and oncology doctors via prescription. Furthermore, the increasing number of pipeline prospects, combined with drug approvals, is expected to accelerate segment development throughout the forecast period.

Liver Cancer Drugs Market: By Region

As per the geographical analysis, the market can be classified into North America (the United States, Canada, and Mexico), Asia Pacific (India, China, Japan, Malaysia, Singapore, and Rest of Asia Pacific), Europe (Germany, United Kingdom, Italy, France, Spain, Netherlands, and Rest of Europe), Middle East & Africa (Saudi Arabia, United Arab Emirates, and Rest of the Middle East & Africa) and Central & South America (Brazil, Argentina, and Rest of Central and South America). North America is the leading market owing to the excellent healthcare facilities being provided. Globally, patients suffering from various types of cancer visit the United States of America for treatment purposes. Medical Councils, hospitals, and the government are working in collaboration with each other in order to find a permanent cure for all types of cancers. The government has been driving various initiatives and programs to make the proper treatment for liver cancer or any other type of cancer affordable and accessible for everyone. Also, North America is home to some of the best pharmaceutical companies across the world who are constantly engaged in research for finding new medicines for a permanent cure to this disease. Also, the biotechnological companies in the region have been working relentlessly in order to find a cure for liver cancer with the help of genetically engineered mutations. The Asia Pacific has been the fastest-growing market owing to the quality of treatment for liver cancer in India and China. China is a lucrative destination for business players, with significant market growth potential. The presence of a large patient demographic and substantial unaddressed health needs is giving a significant boost to the nation's liver cancer therapeutics market.

Liver Cancer Drugs Market Share and Competitor Analysis

4SC AG, Actavis Group Inc., Alnylam Pharmaceuticals Inc., ArQule Inc., Bayer Schering Pharma AG, Bristol-Myers Squibb Company, Celsion Corp, Eli Lilly & Company, ImClone Systems Inc., F. Hoffmann–La Roche Ltd., Jennerex Biotherapeutics Inc., Onyx Pharmaceuticals Inc., Pfizer Inc., Progen Pharmaceuticals Ltd., and Teva Pharmaceutical Industries Ltd. among others are the top players in the liver cancer drugs market.  

Please note: This is not an exhaustive list of companies profiled in the report.